Research at the Novo Nordisk Foundation Center for Vaccines and Immunity

The scientific strategy of the Novo Nordisk Foundation Center for Vaccines and Immunity (NCVI)  is centred on gaining a deeper understanding of protective immune responses, both in the body as a whole and specifically within the respiratory tract. NCVI focus on four key research areas:

• Respiratory Pathogens
• Airway Immunity
• Vaccine Platforms
• Airway Delivery

These areas collectively guide NIVI's efforts to develop new and improved vaccines that induce robust protection against our three priority pathogens:

• Tuberculosis
• Influenza
• Group A Streptococcus

To accomplish this, NIVI is establishing a highly collaborative research environment where interdisciplinary teams work together on crosscutting projects to address key questions within these focus areas.

With NIVI's unique organizational position, the initiative aims to conduct direct side-by-side comparisons of various vaccine technologies and components, including different antigen targets, vaccine platforms, adjuvants, and delivery methods. The outcome of these workflows guides the rational combination of these factors into optimized vaccine candidates that NIVI then evaluates using state-of-the-art infection models and advanced immunological readouts.

The research approach will not only better inform the development of vaccines against our three priority pathogens, but will also generate cutting-edge comparative data that holds significant relevance to the broader vaccine development community.